Clinical trial · Interventional
PET Scan in Treating Patients With Metastatic Prostate Cancer
11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer
NCT00002981CI-TRIAL-00077668completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| methionine C 11 | Radiation | — | UNRESOLVED |
| positron emission tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET Scan
- description
- Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
- interventionNames
- Procedure: positron emission tomography
- Radiation: fludeoxyglucose F 18
- Radiation: methionine C 11
Primary outcomes (3)
- measure
- Overall Survival
- timeFrame
- Up to 9 years
- measure
- Metabolism
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 0 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed prostate adenocarcinoma * Must have an at least 50% increase in PSA which is sustained for a minimum of 3 observations obtained at least 1 week apart * Must have development of new lesions on bone scintigraphy or greater than 50% increase in measurable disease on CT or MRI scan * Metastatic disease PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Karnofsky greater than 60% Hematopoietic: * ANC greater than 1,000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No clinically significant cardiac disease Pulmonary: * No clinically significant pulmonary disease Other: * No active infection not controlled by antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.